---
layout: post
title: 辉瑞开发的Paxlovid已在美国成为治疗新冠的主选药物
date: 2022-05-31 07:33:04.000000000 +08:00
link: https://cn.wsj.com/amp/articles/%E8%BE%89%E7%91%9E%E5%BC%80%E5%8F%91%E7%9A%84paxlovid%E5%B7%B2%E5%9C%A8%E7%BE%8E%E5%9B%BD%E6%88%90%E4%B8%BA%E6%B2%BB%E7%96%97%E6%96%B0%E5%86%A0%E7%9A%84%E4%B8%BB%E9%80%89%E8%8D%AF%E7%89%A9-11653953107
categories: wsj
---

<main id="main" role="main">
<div>


</div>
<div itemprop="articleLead" data-sbId="CN-BIZ-20220531071623">
    <div>
      <div class="media-object scope-
          header
">
          <figure>
      <div>
        <img
          srcset="https://images.wsj.net/im-550876?width=540&amp;size=1.5005861664712778 540w, https://images.wsj.net/im-550876?width=620&amp;size=1.5005861664712778 620w, https://images.wsj.net/im-550876?width=639&amp;size=1.5005861664712778 639w, https://images.wsj.net/im-550876?width=860&amp;size=1.5005861664712778 860w, https://images.wsj.net/im-550876?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=1.5 1290w, https://images.wsj.net/im-550876?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=2 1720w, https://images.wsj.net/im-550876?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=3 2580w"
          src="https://images.wsj.net/im-550876?width=860&amp;height=573"
          layout="responsive"
          placeholder
          alt="">
        </img>
      </div>
      <figcaption>
        <p>辉瑞公司称其对Paxlovid的进展感到满意，该公司预计需求会增加。</p>
    <p> 图片来源：FABIAN SOMMER/PICTURE ALLIANCE/GETTY IMAGES</p>
  </figcaption>
</figure>

      </div>
    </div>
</div>
<div data-sbId="CN-BIZ-20220531071623">

<div>

  <div>
      <p> </p>
              <p><span itemprop="name">
                <a href="https://www.wsj.com/news/author/jared-s-hopkins" itemprop="url" rel="author">Jared S. Hopkins</a>
              </span></p>

  </div>
    <time>
      2022年5月31日07:25 CST 更新
    </time>
</div>

<div>
  <social-share type="system" width="72" height="24"
    data-param-url="https://cn.wsj.com/articles/辉瑞开发的paxlovid已在美国成为治疗新冠的主选药物-11653953107">
  </social-share>
</div>


<div subscriptions-section="content">
</div>
<div subscriptions-section="content-not-granted">
</div>



<section subscriptions-section="content">
      <p>辉瑞公司(Pfizer Inc., PFE)开发的新冠药已经成为美国治疗新冠的最主要处方药，该药的供应情况已经改善，有更多的药房售卖该药。</p>
      <p>根据药物数据公司Iqvia Holdings Inc.的数据，截至5月6日，对于辉瑞公司的抗病毒药物Paxlovid开出的处方总数超过41.2万张，而默克公司(Merck &amp; Co. Inc., MRK)和Ridgeback Biotherapeutics LP的抗病毒药物molnupiravir的处方数约为11万张。</p>
      <p>这两种药物在去年12月被美国食品药品管理局 (Food and Drug Administration, 简称FDA)批准用于病程早期的高风险人群，以保护患者不至病情加重到需要住院治疗。</p>
      <div></div>
</section>

</div>
      </main>
